TrialNature communications2026

Mirvetuximab soravtansine plus pembrolizumab in recurrent folate receptor alpha-positive uterine serous carcinoma: a phase II trial.

Rebecca L Porter et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.